John B. Harlow was named Chief Operating Officer of Larimar Therapeutics, Inc., effective September 29, 2026. As of November 6, 2026, Larimar Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 29, 2026, naming 1 appointment (Form 8-K, September 29, 2026).
Larimar Therapeutics, Inc. named a new Chief Operating Officer on Sep 29. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Larimar Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Larimar Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Larimar Therapeutics, Inc. files it.
Also on the record for Larimar Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP | 9.99% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 3.5% of the class | 5%+ stakes | Source |
| March 2, 2026 | Stake report, Schedule 13D/A, by James E. Flynn | 34.41% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Blue Owl Capital Holdings LP | 9.99% of the class | 5%+ stakes | Source |
| November 6, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 5.8% of the class | 5%+ stakes | Source |
| August 29, 2025 | Stake report, Schedule 13G, by Opaleye Management, Inc. | 4.8% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | — | 5%+ stakes | Source |
| July 31, 2025 | Stake report, Schedule 13D/A, by James E. Flynn | 35.81% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Larimar Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Larimar Therapeutics, Inc. and the records around it.
Larimar Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026)
- Opaleye Management, Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
- Deerfield Private Design Fund III, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
Watch Larimar Therapeutics, Inc.
Get an email when Larimar Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Larimar Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Larimar Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Larimar Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-29 | In | Chief Operating Officer | 2026-09-29 | 8-K, 2026-09-29 |
Who leads Larimar Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: John B. Harlow, appointed, effective 2026-09-29 (filed 2026-09-29).
New leaders reset buying decisions — get the Full Report on Larimar Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Larimar Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Larimar Therapeutics, Inc.Every change, in the filing's words
Appointed: John B. Harlow, Chief Operating Officer, effective 2026-09-29
The Board of Directors (the "Board") of Larimar Therapeutics, Inc. (the "Company") appointed John B. Harlow, Jr. as the Company's President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the "Employment Agreement"), effective as of September 29, 2026 (the "Effective Date").
- Prior to joining the Company, Mr. Harlow, age 51, served as the Chief Commercial Officer at Esperion Therapeutics, Inc. (formerly Nasdaq: ESPR), a commercial stage biopharmaceutical company focused on developing medicines for patients who are at risk for cardiovascular disease, from November 2025 to September 2026, where he led commercial operations, business development and global alliance management.
- From March 2021 to November 2025, Mr. Harlow served as the Chief Commercial Officer of Melinta Therapeutics, LLC, a commercial stage company focused on innovative therapies for acute and life-threatening illnesses, where he built a robust commercial infrastructure with a high-performing team while achieving significant revenue growth and sustained profitability ahead of its 2025 acquisition by CorMedix.
- From November 2019 to March 2021, Mr. Harlow was Chief Commercial Officer at Baudax Bio, Inc. (formerly Nasdaq: BXRX), a commercial stage company focused on therapeutics for acute care settings.
- From October 2016 to November 2019, Mr. Harlow served in commercial leadership roles of increasing responsibility at Recro Pharma, Inc. (formerly Nasdaq: REPH), including as Executive Vice President and Vice President.
Tools for this story
Each opens in a new tab, filled in for Larimar Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.